RIDA

Summary

RIDA (reactive intermediate imine deaminase A, HGNC:16897) is a protein-coding gene on chromosome 8q22.2, encoding 2-iminobutanoate/2-iminopropanoate deaminase (P52758). Catalyzes the hydrolytic deamination of enamine/imine intermediates that form during the course of normal metabolism.

Enables mRNA binding activity. Involved in mRNA catabolic process and mRNA destabilization. Located in cytoplasm and nucleus.

Source: NCBI Gene 10247 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 10 total
• MANE Select transcript: NM_005836

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16897
Approved symbol	RIDA
Name	reactive intermediate imine deaminase A
Location	8q22.2
Locus type	gene with protein product
Status	Approved
Aliases	UK114, P14.5, PSP
Ensembl gene	ENSG00000132541
Ensembl biotype	protein_coding
OMIM	602487
Entrez	10247

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000254878, ENST00000519155, ENST00000519608, ENST00000520507, ENST00000521560, ENST00000522791, ENST00000883921, ENST00000883922, ENST00000883923, ENST00000883924

RefSeq mRNA: 1 — MANE Select: NM_005836 NM_005836

CCDS: CCDS6276

Canonical transcript exons

ENST00000254878 — 6 exons

Exon	Start	End
ENSE00001026779	98102344	98102904
ENSE00001382719	98108646	98108751
ENSE00002126599	98117032	98117171
ENSE00003534460	98104489	98104544
ENSE00003611300	98105938	98106006
ENSE00003630276	98106272	98106326

Expression profiles

Bgee: expression breadth ubiquitous, 272 present calls, max score 99.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.3184 / max 1136.7563, expressed in 1765 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
94082	19.4758	1755
94081	3.8426	1287

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	99.56	gold quality
liver	UBERON:0002107	99.04	gold quality
adult mammalian kidney	UBERON:0000082	98.42	gold quality
adrenal tissue	UBERON:0018303	97.70	gold quality
nephron tubule	UBERON:0001231	97.58	gold quality
caudate nucleus	UBERON:0001873	97.20	gold quality
nucleus accumbens	UBERON:0001882	97.12	gold quality
kidney epithelium	UBERON:0004819	97.11	gold quality
putamen	UBERON:0001874	96.75	gold quality
kidney	UBERON:0002113	96.69	gold quality
amygdala	UBERON:0001876	96.54	gold quality
renal glomerulus	UBERON:0000074	96.36	gold quality
anterior cingulate cortex	UBERON:0009835	96.23	gold quality
cingulate cortex	UBERON:0003027	96.18	gold quality
right adrenal gland cortex	UBERON:0035827	96.04	gold quality
hypothalamus	UBERON:0001898	95.99	gold quality
metanephric glomerulus	UBERON:0004736	95.97	gold quality
right adrenal gland	UBERON:0001233	95.89	gold quality
cortex of kidney	UBERON:0001225	95.80	gold quality
right frontal lobe	UBERON:0002810	95.67	gold quality
left adrenal gland	UBERON:0001234	95.35	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.34	gold quality
left adrenal gland cortex	UBERON:0035825	95.07	gold quality
middle frontal gyrus	UBERON:0002702	94.98	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	94.81	gold quality
substantia nigra	UBERON:0002038	94.77	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	94.74	gold quality
metanephros	UBERON:0000081	94.56	gold quality
adrenal cortex	UBERON:0001235	94.45	gold quality
adrenal gland	UBERON:0002369	94.27	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-124472	yes	531.99
E-HCAD-10	yes	439.78
E-MTAB-10553	yes	37.66
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

29 targeting RIDA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-130B-5P	99.83	68.50	1888
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-130A-5P	99.33	70.26	2623
HSA-MIR-410-3P	99.27	69.98	2457
HSA-MIR-12135	98.99	70.26	1814
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-6074	98.89	69.64	2187
HSA-MIR-320A-5P	98.88	66.75	1248
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-6868-3P	98.63	69.64	2259
HSA-MIR-4518	98.12	66.82	1030
HSA-MIR-337-3P	97.90	69.37	1052
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-6750-3P	96.79	67.50	740
HSA-MIR-4695-3P	96.71	67.21	836
HSA-MIR-6760-3P	96.35	68.31	1001

Literature-anchored findings (GeneRIF, showing 5)

• x-ray crystallography study of p14.5 (PMID:14997576)
• analysis of ligand binding sites of protein p14.5 (PMID:16198412)
• We also find that a subset of m(6)A-containing circular RNAs associates with YTHDF2 in an HRSP12-dependent manner and is selectively downregulated by RNase P/MRP. (PMID:30930054)
• The new findings regarding the biological significance of enamine and imine production and outline the importance of RidA in controlling the accumulation of reactive metabolites. (PMID:31103411)
• P14.5 functions to inhibit cell migration and can be used as a prognostic marker in hepatocellular carcinoma. (PMID:36434386)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rida	ENSDARG00000035882
mus_musculus	Rida	ENSMUSG00000022323
rattus_norvegicus	Rida	ENSRNOG00000005437
drosophila_melanogaster	UK114	FBGN0086691
caenorhabditis_elegans		WBGENE00016011

Protein

Protein identifiers

2-iminobutanoate/2-iminopropanoate deaminase — P52758 (reviewed: P52758)

Alternative names: 14.5 kDa translational inhibitor protein, Heat-responsive protein 12, Reactive intermediate imine deaminase A homolog, Translation inhibitor L-PSP ribonuclease, UK114 antigen homolog

All UniProt accessions (4): P52758, E5RIP8, H0YB34, H0YBX3

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the hydrolytic deamination of enamine/imine intermediates that form during the course of normal metabolism. May facilitate the release of ammonia from these potentially toxic reactive metabolites, reducing their impact on cellular components. It may act on enamine/imine intermediates formed by several types of pyridoxal-5’-phosphate-dependent dehydratases including L-threonine dehydratase. Also promotes endoribonucleolytic cleavage of some transcripts by promoting recruitment of the ribonuclease P/MRP complex. Acts by bridging YTHDF2 and the ribonuclease P/MRP complex. RIDA/HRSP12 binds to N6-methyladenosine (m6A)-containing mRNAs containing a 5’-GGUUC-3’ motif: cooperative binding of RIDA/HRSP12 and YTHDF2 to such transcripts lead to recruitment of the ribonuclease P/MRP complex and subsequent endoribonucleolytic cleavage.

Subunit / interactions. Homotrimer. Interacts with YTHDF2.

Subcellular location. Cytoplasm. Nucleus. Peroxisome. Mitochondrion.

Tissue specificity. Expressed predominantly in liver and kidney. Lower levels in lung and brain.

Similarity. Belongs to the RutC family.

RefSeq proteins (1): NP_005827* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006056	RidA	Family
IPR006175	YjgF/YER057c/UK114	Family
IPR019897	RidA_CS	Conserved_site
IPR035959	RutC-like_sf	Homologous_superfamily

Pfam: PF01042

Catalyzed reactions (Rhea), 2 shown:

• 2-iminobutanoate + H2O = 2-oxobutanoate + NH4(+) (RHEA:39975)
• 2-iminopropanoate + H2O = pyruvate + NH4(+) (RHEA:40671)

UniProt features (23 total): strand 8, modified residue 6, helix 5, initiator methionine 1, chain 1, turn 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9N80	X-RAY DIFFRACTION	1.39
1ONI	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P52758-F1	97.12	0.96

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 2, 13, 60, 67, 74, 136

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8849175	Threonine catabolism

MSigDB gene sets: 210 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_DN, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, GOMF_ENDONUCLEASE_ACTIVITY, GOMF_RNA_NUCLEASE_ACTIVITY, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GOMF_NUCLEASE_ACTIVITY, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, GOBP_SERINE_FAMILY_AMINO_ACID_BIOSYNTHETIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS

GO Biological Process (8): mRNA catabolic process (GO:0006402), lipid metabolic process (GO:0006629), negative regulation of translation (GO:0017148), obsolete L-threonine catabolic process to glycine (GO:0019518), mRNA destabilization (GO:0061157), post-transcriptional regulation of gene expression (GO:0010608), negative regulation of gene expression (GO:0010629), regulation of primary metabolic process (GO:0080090)

GO Molecular Function (9): RNA binding (GO:0003723), mRNA binding (GO:0003729), RNA endonuclease activity producing 3’-phosphomonoesters, hydrolytic mechanism (GO:0016892), deaminase activity (GO:0019239), 2-iminobutanoate deaminase activity (GO:0120242), 2-iminopropanoate deaminase activity (GO:0120243), protein binding (GO:0005515), hydrolase activity (GO:0016787), 2-iminobutanoate/2-iminopropanoate deaminase activity (GO:0120241)

GO Cellular Component (7): nucleus (GO:0005634), cytoplasm (GO:0005737), mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), peroxisome (GO:0005777), cytosol (GO:0005829), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of amino acids and derivatives	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of gene expression	3
primary metabolic process	2
regulation of gene expression	2
2-iminobutanoate/2-iminopropanoate deaminase activity	2
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
cytoplasm	2
RNA catabolic process	1
mRNA metabolic process	1
translation	1
regulation of translation	1
negative regulation of protein metabolic process	1
regulation of mRNA stability	1
RNA destabilization	1
positive regulation of mRNA catabolic process	1
gene expression	1
negative regulation of macromolecule biosynthetic process	1
regulation of metabolic process	1
nucleic acid binding	1
RNA binding	1
RNA endonuclease activity	1
hydrolase activity, acting on ester bonds	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	1
binding	1
catalytic activity	1
deaminase activity	1
intracellular anatomical structure	1
mitochondrion	1
intracellular organelle lumen	1
microbody	1
extracellular vesicle	1

Protein interactions and networks

STRING

1805 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RIDA	YTHDF2	Q9Y5A9	989
RIDA	CNOT1	A5YKK6	554
RIDA	YTHDC1	Q96MU7	542
RIDA	YTHDF3	Q7Z739	516
RIDA	DPH3	Q96FX2	506
RIDA	DPH6	Q7L8W6	499
RIDA	DPH5	Q9H2P9	493
RIDA	UPF1	Q92900	492
RIDA	DPH7	Q9BTV6	490
RIDA	YTHDF1	Q9BYJ9	490
RIDA	YTHDC2	Q9H6S0	489
RIDA	METTL3	Q86U44	488
RIDA	PNRC2	Q9NPJ4	462
RIDA	DPH2	Q9BQC3	459
RIDA	DPH1	Q9BZG8	459

IntAct

22 interactions, top by confidence:

A	B	Type	Score
RIDA	BANP	psi-mi:“MI:0915”(physical association)	0.560
RIDA	RIDA	psi-mi:“MI:0915”(physical association)	0.370
DEAF1	RIDA	psi-mi:“MI:0915”(physical association)	0.370
RIDA	HIVEP1	psi-mi:“MI:0915”(physical association)	0.370
HPD	RIDA	psi-mi:“MI:0915”(physical association)	0.370
MDM2	RIDA	psi-mi:“MI:0915”(physical association)	0.370
RIDA	MT-CO2	psi-mi:“MI:0915”(physical association)	0.370
RIDA	SERPINA5	psi-mi:“MI:0915”(physical association)	0.370
SPEN	RIDA	psi-mi:“MI:0915”(physical association)	0.370
RIDA	TMEM176A	psi-mi:“MI:0915”(physical association)	0.370
PRNP	SYNJ1	psi-mi:“MI:0914”(association)	0.350
PRNP	MBP	psi-mi:“MI:0914”(association)	0.350
RIDA	OGA	psi-mi:“MI:0914”(association)	0.350
NDUFS3	ACOT7	psi-mi:“MI:0914”(association)	0.350
	SHTN1	psi-mi:“MI:0914”(association)	0.350
FTSJ1	RIDA	psi-mi:“MI:0915”(physical association)	0.000
TRAF6	RIDA	psi-mi:“MI:0915”(physical association)	0.000
RIDA	BANP	psi-mi:“MI:0915”(physical association)	0.000
RIDA	alr	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (47): HRSP12 (Two-hybrid), BROX (Co-fractionation), TPI1 (Co-fractionation), ACOX1 (Affinity Capture-MS), CARM1 (Affinity Capture-MS), UBB (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), BANP (Two-hybrid), HRSP12 (Proximity Label-MS), HRSP12 (Proximity Label-MS), ACOX1 (Affinity Capture-MS), MGEA5 (Affinity Capture-MS), CARM1 (Affinity Capture-MS), UBB (Affinity Capture-MS), HRSP12 (Two-hybrid)

ESM2 similar proteins: A0A1J1DL12, A4W923, A6T7A0, A8GCT4, B0SW61, B5XXN2, B6I986, B7N3G6, B8H1Q2, B9JLT7, C5B0U7, C5CN81, C9Y0S5, D0LI57, D3QPK3, D3RKL2, D4GEU6, D5CE34, D5VGV2, O25598, O34133, O52178, P0AF93, P0AF94, P0AF95, P0AFQ5, P0AGL2, P0AGL3, P0AGL4, P40037, P40185, P40431, P44839, P52758, P52759, P52760, P55654, P80601, Q3T114, Q48MQ6

Diamond homologs: A0A1J1DL12, A6T7A0, A8IAD2, B0SW61, B1M5I6, B1ZB17, B5XXN2, D0LI57, D3RKL2, O25598, O34133, O43003, O52178, O58584, O66689, P0AF93, P0AF94, P0AF95, P0AGL2, P0AGL3, P0AGL4, P37552, P40037, P40185, P40431, P44839, P52758, P52759, P52760, P52761, P55654, P57452, P80601, P97117, Q10121, Q3T114, Q6FFZ5, Q7CP78, Q89AG0, Q8K9H7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

10 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

685 predictions. Top by Δscore:

Variant	Effect	Δscore
8:98102903:CCCTG:C	acceptor_loss	1.0000
8:98102905:C:A	acceptor_loss	1.0000
8:98105932:A:AC	donor_gain	1.0000
8:98105932:ACTT:A	donor_loss	1.0000
8:98105933:C:CC	donor_gain	1.0000
8:98105934:TTACA:T	donor_loss	1.0000
8:98105935:TA:T	donor_loss	1.0000
8:98105936:A:AC	donor_gain	1.0000
8:98105936:ACAC:A	donor_loss	1.0000
8:98105937:C:CA	donor_gain	1.0000
8:98105937:CA:C	donor_gain	1.0000
8:98105937:CACT:C	donor_gain	1.0000
8:98105937:CACTG:C	donor_gain	1.0000
8:98106002:CACCA:C	acceptor_gain	1.0000
8:98106003:ACCA:A	acceptor_gain	1.0000
8:98106004:CCA:C	acceptor_gain	1.0000
8:98106004:CCAC:C	acceptor_gain	1.0000
8:98106005:CA:C	acceptor_gain	1.0000
8:98106005:CAC:C	acceptor_gain	1.0000
8:98106006:ACTAG:A	acceptor_loss	1.0000
8:98106007:C:CC	acceptor_gain	1.0000
8:98106007:CT:C	acceptor_loss	1.0000
8:98106008:T:C	acceptor_loss	1.0000
8:98106267:CTCA:C	donor_loss	1.0000
8:98106268:TCA:T	donor_loss	1.0000
8:98106269:CAC:C	donor_loss	1.0000
8:98106270:ACCG:A	donor_loss	1.0000
8:98108644:A:AC	donor_gain	1.0000
8:98108645:C:CC	donor_gain	1.0000
8:98102900:CTGCC:C	acceptor_gain	0.9900

AlphaMissense

876 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:98108747:C:G	A24P	0.987
8:98102883:C:G	A125P	0.986
8:98105991:A:T	V81D	0.983
8:98104512:A:C	Y110D	0.979
8:98106000:T:A	K78I	0.979
8:98104523:G:T	A106D	0.978
8:98104519:T:A	R107S	0.976
8:98104519:T:G	R107S	0.976
8:98102876:G:T	A127D	0.975
8:98105988:A:G	L82P	0.975
8:98102882:G:T	A125E	0.974
8:98104496:A:G	L115S	0.974
8:98108654:C:G	A55P	0.973
8:98105958:A:T	V92D	0.972
8:98108713:C:T	G35E	0.972
8:98106301:A:G	L66P	0.970
8:98102890:T:A	E122D	0.969
8:98102890:T:G	E122D	0.969
8:98105966:G:C	F89L	0.969
8:98105966:G:T	F89L	0.969
8:98105968:A:G	F89L	0.969
8:98108746:G:T	A24D	0.969
8:98104518:C:G	A108P	0.967
8:98105999:T:A	K78N	0.967
8:98105999:T:G	K78N	0.967
8:98108704:C:T	G38D	0.967
8:98104514:G:T	A109D	0.965
8:98104526:G:T	P105H	0.964
8:98108713:C:A	G35V	0.964
8:98105954:A:C	N93K	0.963

dbSNP variants (sampled 300 via entrez): RS1000187597 (8:98111423 C>T), RS1000344019 (8:98118097 C>T), RS1000662520 (8:98109325 T>C), RS1000676032 (8:98116743 C>A,G), RS1000725587 (8:98111102 T>C), RS1000928429 (8:98109634 C>T), RS1001017629 (8:98118630 T>C), RS1001257510 (8:98103737 T>C,G), RS1001448124 (8:98110551 C>T), RS1001575364 (8:98117721 C>A), RS1001825853 (8:98108493 A>G), RS1002053667 (8:98117408 G>A), RS1002244119 (8:98106442 T>A), RS1002248399 (8:98116339 C>T), RS1002394458 (8:98113421 T>C)

Disease associations

OMIM: gene MIM:602487 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001762_746	Obesity-related traits	6.000000e-07
GCST006585_1707	Blood protein levels	6.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0003939	energy intake

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tretinoin	decreases expression	3
Cyclosporine	decreases expression	3
Aflatoxin B1	decreases methylation, affects expression, decreases expression	3
bisphenol A	affects expression, decreases expression	2
Benzo(a)pyrene	decreases expression, increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
Esketamine	decreases expression	1
dicrotophos	decreases expression	1
methyleugenol	decreases expression	1
arsenite	increases reaction, affects binding	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
K 7174	decreases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
bisphenol S	increases expression	1
MT19c compound	increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, decreases expression	1
Azathioprine	decreases expression	1
Oxygen	decreases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SR66	HAP1 HRSP12 (-) 1	Cancer cell line	Male
CVCL_SR67	HAP1 HRSP12 (-) 2	Cancer cell line	Male
CVCL_SR68	HAP1 HRSP12 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.